104 related articles for article (PubMed ID: 38772871)
1. Synchronous skull base and spinal metastases in a patient with treatment-resistant, high-grade serous adenocarcinoma of tubo-ovarian origin.
Ziegler J; El-Shakankery KH; Hyare H; Flynn M
BMJ Case Rep; 2024 May; 17(5):. PubMed ID: 38772871
[TBL] [Abstract][Full Text] [Related]
2. Intradural extramedullary spinal metastasis from an ovarian carcinoma.
Mehrotra R; Sharma K
Indian J Cancer; 2002; 39(4):157-60. PubMed ID: 12928577
[TBL] [Abstract][Full Text] [Related]
3. Coexistent intramedullary spinal cord and choroidal metastases in ovarian cancer.
Kodama M; Kawaguchi H; Komoto Y; Takemura M
J Obstet Gynaecol Res; 2010 Feb; 36(1):199-203. PubMed ID: 20178552
[TBL] [Abstract][Full Text] [Related]
4. BRCA mutational status, initial disease presentation, and clinical outcome in high-grade serous advanced ovarian cancer: a multicenter study.
Petrillo M; Marchetti C; De Leo R; Musella A; Capoluongo E; Paris I; Benedetti Panici P; Scambia G; Fagotti A
Am J Obstet Gynecol; 2017 Sep; 217(3):334.e1-334.e9. PubMed ID: 28549976
[TBL] [Abstract][Full Text] [Related]
5. Intramedullary spinal cord metastasis from ovarian carcinoma.
Cormio G; Di Vagno G; Di Fazio F; Loverro G; Selvaggi L
Gynecol Oncol; 2001 Jun; 81(3):506-8. PubMed ID: 11371147
[TBL] [Abstract][Full Text] [Related]
6. Intramedullary spinal cord metastases from epithelial ovarian carcinoma.
Thomas AW; Simon SR; Evans C
Gynecol Oncol; 1992 Feb; 44(2):195-7. PubMed ID: 1544599
[TBL] [Abstract][Full Text] [Related]
7. Upfront debulking surgery versus interval debulking surgery for advanced tubo-ovarian high-grade serous carcinoma and diffuse peritoneal metastases treated with peritonectomy procedures plus HIPEC.
Biacchi D; Accarpio F; Ansaloni L; Macrì A; Ciardi A; Federici O; Spagnoli A; Cavaliere D; Vaira M; Sapienza P; Sammartino P
J Surg Oncol; 2019 Dec; 120(7):1208-1219. PubMed ID: 31531879
[TBL] [Abstract][Full Text] [Related]
8. Ovarian low-grade serous carcinoma involving the cervix mimicking a cervical primary.
Malpica A; Deavers MT
Int J Gynecol Pathol; 2011 Nov; 30(6):613-9. PubMed ID: 21979600
[TBL] [Abstract][Full Text] [Related]
9. Successful complete regression of isolated intramedullary spinal cord metastases from epithelial ovarian carcinoma with chemotherapy and radiotherapy.
Bakshi A; Biswas G; Deshmukh C; Prasad N; Nair R; Parikh PM
Indian J Cancer; 2006; 43(3):136-8. PubMed ID: 17065773
[TBL] [Abstract][Full Text] [Related]
10. Epithelial Ovarian Cancer Metastatic to the Central Nervous System and a Family History Concerning for Hereditary Breast and Ovarian Cancer--A Potential Relationship.
Jernigan AM; Mahdi H; Rose PG
Int J Gynecol Cancer; 2015 Sep; 25(7):1232-8. PubMed ID: 26067864
[TBL] [Abstract][Full Text] [Related]
11. Serous carcinoma of the ovary and peritoneum with metastases to the breast and axillary lymph nodes: a potential pitfall.
Recine MA; Deavers MT; Middleton LP; Silva EG; Malpica A
Am J Surg Pathol; 2004 Dec; 28(12):1646-51. PubMed ID: 15577686
[TBL] [Abstract][Full Text] [Related]
12. Ovarian carcinoma metastatic to the breast.
Wadhwa J; Dawar R; Kumar L
Clin Oncol (R Coll Radiol); 1999; 11(6):419-21. PubMed ID: 10663336
[TBL] [Abstract][Full Text] [Related]
13. Type-specific response to neoadjuvant chemotherapy: ovarian high-grade serous carcinoma versus colorectal mucinous carcinoma.
Glaze S; Nation J; Köbel M
J Obstet Gynaecol Can; 2012 Jul; 34(7):678-82. PubMed ID: 22742488
[TBL] [Abstract][Full Text] [Related]
14. Niraparib as maintenance therapy in a patient with ovarian cancer and brain metastases.
Gray S; Khor XY; Yiannakis D
BMJ Case Rep; 2019 Aug; 12(8):. PubMed ID: 31466953
[TBL] [Abstract][Full Text] [Related]
15. Germline BRCA, chemotherapy response scores, and survival in the neoadjuvant treatment of ovarian cancer.
Lee YJ; Kim HS; Rim JH; Lee JY; Nam EJ; Kim SW; Kim S; Kim YT
BMC Cancer; 2020 Mar; 20(1):185. PubMed ID: 32131779
[TBL] [Abstract][Full Text] [Related]
16. Serous ovarian and primary peritoneal cancers: A comparative analysis of clinico-pathological features, molecular subtypes and treatment outcome.
Gao B; Lindemann K; Anderson L; Fereday S; Hung J; Alsop K; Tothill RW; Gebski V; Kennedy C; Balleine RL; ; Harnett PR; Bowtell DD; DeFazio A
Gynecol Oncol; 2016 Sep; 142(3):458-64. PubMed ID: 27444035
[TBL] [Abstract][Full Text] [Related]
17. Spinal intramedullary uterine carcinosarcoma metastasis.
Solis W; Youssef AM; Shaw R; Li Y
BMJ Case Rep; 2024 Feb; 17(2):. PubMed ID: 38417940
[TBL] [Abstract][Full Text] [Related]
18. Low-grade serous ovarian carcinoma: an evolution toward targeted therapy.
Voutsadakis IA
Int J Gynecol Cancer; 2020 Oct; 30(10):1619-1626. PubMed ID: 31780569
[TBL] [Abstract][Full Text] [Related]
19. A detailed morphological and immunohistochemical comparison of primary endometrial and tubo-ovarian high-grade serous carcinomas and their corresponding omental metastases.
Ruba S; Doherty D; Stewart CJR
Pathology; 2020 Feb; 52(2):197-205. PubMed ID: 31870502
[TBL] [Abstract][Full Text] [Related]
20. Prognostic significance of supraclavicular lymphadenopathy in patients with high-grade serous ovarian cancer.
Cybulska P; Hayes SA; Spirtos A; Rafizadeh MJ; Filippova OT; Leitao M; Zivanovic O; Sonoda Y; Mueller J; Lakhman Y; Long K; Chi DS
Int J Gynecol Cancer; 2019 Nov; 29(9):1377-1380. PubMed ID: 31575614
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
